RESEARCH MONOGRAPH · KDC-MN-397

L-Arginine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

72/100

Mostly destroyed by first-pass arginase; the supplement version is much weaker than citrulline at delivering arginine

L-arginine is the classic example of a supplement whose pharmacology was misunderstood for years. The textbook story is: arginine is the substrate for nitric oxide synthase, supplementing arginine should elevate NO production, and NO does useful cardiovascular and ergogenic things. All of which is true except for the supplementation part.

The actual pharmacokinetics are uncooperative. Oral L-arginine is heavily metabolized in the gut and liver by arginase, which converts it to ornithine and urea before it ever reaches systemic circulation. So oral arginine at typical supplement doses (3 to 6 g) produces only modest and brief elevation of plasma arginine. The Schwedhelm and Bode-Boger work demonstrated this clearly: citrulline supplementation produces higher and longer plasma arginine elevation than equivalent oral arginine itself, because citrulline bypasses arginase first-pass metabolism.

The clinical literature reflects this PK problem. Older trials showing endothelial improvement with oral arginine generally used very high doses (10 g or more) or IV administration, which got around the first-pass issue. Trials at typical supplement doses are mixed at best and often null. The cardiovascular outcomes literature (VINTAGE MI, the post-MI trial that showed worse outcomes with arginine) was the wake-up call that 'feed the substrate' is not always a clean strategy.

What we like: high-dose IV L-arginine remains useful as a tool compound in pituitary stimulation testing for growth hormone secretory capacity. That's a clinical endocrinology use that survives the pharmacokinetic skepticism.

What we don't like is the general supplement market positioning of L-arginine as a 'nitric oxide booster' when citrulline is the better-evidenced precursor for that purpose. The pump-and-NO products mostly should be citrulline-based, and the better ones are.

Sourcing is trivially easy. L-arginine is one of the cheapest standard amino acids, HPLC purity from competent suppliers is reliably 99 plus, stability is excellent. Both the HCl salt and freebase forms are common, the HCl salt is more soluble and stable in solution.

Staying power is moderate. The amino acid biology isn't going anywhere but its role as a useful supplement is much smaller than the marketing suggests.

Evidence: 60
Mechanism: 80
Reliability: 55
Safety: 85
Sourcing: 92
Value: 85
Signal: 50
Staying power: 65

Plain-language summary Intrigue 40 / 100

L-arginine is a conditionally essential amino acid that serves as the direct substrate for nitric oxide synthase (the enzyme that builds NO) and as a urea cycle intermediate for ammonia clearance. Despite being the literal substrate, oral arginine is a surprisingly poor way to raise nitric oxide because intestinal and liver arginase chew through most of it before it reaches systemic circulation. Citrulline, which bypasses arginase by converting to arginine in the kidney, is paradoxically more effective at raising plasma arginine. Cardiovascular research has tested arginine for endothelial dysfunction, peripheral artery disease, and erectile dysfunction with mixed and underwhelming results. Reference NOS substrate amino acid in research, more useful as a comparator than a therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Conditionally essential amino acid / nitric oxide precursor

L-arginine; the direct substrate for nitric oxide synthase and a urea cycle intermediate; used as a pre-workout supplement and in cardiovascular research.

Abstract

L-arginine ((S)-2-amino-5-guanidinopentanoic acid; CAS 74-79-3; molecular formula C6H14N4O2; molecular weight 174.20) is a conditionally essential alpha-amino acid that serves as the direct substrate for nitric oxide synthase (NOS), producing NO and citrulline; arginine is also the rate-limiting urea cycle intermediate for ammonia clearance. Despite the direct NOS substrate role, oral arginine supplementation has limited efficacy at increasing systemic NO production because intestinal and hepatic arginase metabolizes arginine to ornithine before it reaches systemic circulation; citrulline, which is converted to arginine in the kidney bypassing arginase, is paradoxically more effective at raising plasma arginine. Clinical research has investigated arginine for cardiovascular conditions (endothelial dysfunction, peripheral artery disease, erectile dysfunction) with mixed results. Plasma half-life is approximately 1 to 2 hours. Used as the canonical NOS substrate amino acid in research.

Mechanism of action

Direct nitric oxide synthase substrate; urea cycle intermediate. Intestinal arginase limits oral bioavailability for systemic NO production.

Reported research dose ranges

Reported research dose ranges vary across the published literature.

References

Bode-Boger SM, et al. L-arginine and the cardiovascular system. Pharmacol Ther 2007.
Wu G, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009.
Schwedhelm E, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine. Br J Clin Pharmacol 2008.

Read the full monograph

Available as a research-use-only PDF download.

KDC-MN-397

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

L-Arginine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs